PA
SI

SQ Innovation

Pioneering subcutaneous drug-device combos for cost-effective at-home heart failure decongestion, reducing hospital burden.

Visit Website

Known For

Novel high-concentration (30mg/mL) room-temperature stable furosemide enabled by Captisol

Key Differentiators

  • Novel high-concentration (30mg/mL) room-temperature stable furosemide enabled by Captisol
  • cost-effective reusable infusor (48 uses) with disposable cartridge
  • enables at-home treatment reducing hospitalization costs
  • environmentally considerate design

Overview

SQ Innovation is a biopharmaceutical company developing and commercializing innovative drug-device combinations for subcutaneous delivery to enable at-home treatment of conditions typically requiring hospitalization. Their lead product, Lasix ONYU (furosemide injection 80mg/2.67mL), FDA-approved in October 2025, treats edema in chronic heart failure patients via a reusable infusor and disposable cartridge, offering controlled diuresis comparable to IV without hospital visits. The high-concentration formulation uses Captisol technology under license from Ligand Pharmaceuticals.

Services & Capabilities

  • Development and commercialization of subcutaneous drug-device combinations, including Lasix ONYU for at-home heart failure treatment
  • distribution partnerships with Cardinal Health SPD and Cencora Specialty Distribution.

Competitive Position

  • Novel high-concentration (30mg/mL) room-temperature stable furosemide enabled by Captisol
  • cost-effective reusable infusor (48 uses) with disposable cartridge
  • enables at-home treatment reducing hospitalization costs
  • environmentally considerate design

Recent Developments

FDA approval of Lasix ONYU (Oct 7, 2025); Series B financing closed (Oct 2025); product available for order via Cardinal Health and Cencora (Feb 2026); expanded US operations to Woburn MA (Nov 2025); new board members (Oct 2025)

Client & Partner Ecosystem

Ligand Pharmaceuticals (Captisol license/supply), Cardinal Health Specialty Pharmaceutical Distribution, Cencora Specialty Distribution, Gerresheimer (device collaboration); discussions with IDNs, pay

Technology Platform

Lasix ONYU Infusor (reusable motorized on-body device with prefilled cartridge)

Therapeutic Focus

Cardiology (heart failure)

Target Customers

Healthcare providers (hospitals, IDNs, heart failure programs), pharmacies, payors, patients with chronic heart failure

Sources